A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD.

Saved in:
Bibliographic Details
Title: A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD.
Authors: Ebner LJA; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Imsand C; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Karademir D; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Peters F; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Kiessling E; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Fottner A; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Matter C; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Fajardo DS; Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32601, USA., Merolla L; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Wögenstein GM; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Tsioti I; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Govers LP; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Blaser F; Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland., Meneau I; Department of Ophthalmology, University Hospital Zurich, 8091 Zurich, Switzerland., Boye SL; Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, FL 32610, USA., Boye SE; Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, FL 32610, USA., Grimm C; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland., Samardzija M; Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952 Zurich, Switzerland. Electronic address: marijana.samardzija@usz.uzh.ch.
Source: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2026 Jan 07; Vol. 34 (1), pp. 348-366. Date of Electronic Publication: 2025 Sep 27.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1525-0024
DOI:10.1016/j.ymthe.2025.09.044